A phase 4 study of the safety of the 13-valent pneumococcal conjugate vaccine in children 6 to 17 years of age in India
CONCLUSION: PCV13 vaccination was well tolerated with an acceptable safety profile in healthy subjects aged 6 to 17 years in India. This work further supports the safety profile of PCV13 for prevention of pneumococcal disease in this age group in India.PMID:34366142 | DOI:10.1016/j.vaccine.2021.07.055
Source: Vaccine - Category: Allergy & Immunology Authors: Jugesh Chhatwal Amita Sapru Balasubramanian Sundaram Bhaskar Shenoy Rohit Chand Kevin Yi Suresh Suroju Daniel A Scott Stephen Lockhart Source Type: research
More News: Allergy & Immunology | Children | Hepatitis | Hepatitis Vaccine | India Health | Meningitis Vaccine | Pain | Pneomococcal Vaccine | Study | Vaccines